Keywords: AstraZeneca, Onglyza, Label change, Bristol-Myers Squibb, Diabetes

US label update for AstraZeneca/B-MS’ Onglyza for renally-impaired diabetics

Article | 24 February 2011

Print This

The US Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in